Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report

Victor Tetz,1,* Kristina Kardava,1,* Olzhas Shulenbayev,2,* Maria Vecherkovskaya,1 Alireza Khodadadi-Jamayran,3 Aristotelis Tsirigos,3– 5 George Tetz1,6,7,* 1Human Microbiology Institute, New York, NY, 10013, USA; 2Private Hospital International Almaty, Almaty, Kazakhstan; 3Applied Bioinformatics Laboratories, Division of Advanced Research Technologies, NYU School of Medicine, New York, NY, 10016, USA; 4Department of Pathology, NYU School of Medicine, New York, NY, 10016, USA; 5Department of Medicine, Division of Precision Medicine, NYU School of Medicine, New York, NY, 10016, USA; 6Tetz-Laboratories, New York, NY, 10013, USA; 7Second Life Therapeutics, New York, NY, 10014, USA*These authors contributed equally to this workCorrespondence: George Tetz, Email [email protected]: Prostate cancer is the most common malignancy among older man and often a challenge owing to its rapid spread and age-related comorbidities. SL-28 (Leukocyte-Tells) is a novel cell therapy that uses allogeneic leukocytes whose anticancer activity is altered ex vivo using the recently discovered Universal Receptive System.Patients and Methods: A 79-year-old man with Т2сNOMx1, Gleason 7 (3+4) adenocarcinoma of the prostate, with a total PSA level of 10.6 ng/mL and free PSA:total PSA ratio of 11.4% received hormone therapy. Due to an insufficient clinical response and poor tolerance to the therapy, the patient underwent novel allogeneic SL-28 cell therapy.Results: SL-28 therapy was well-tolerated, with no serious adverse effects. The levels of laboratory markers of prostate cancer, such as prostate-specific antigen, gradually improved from the second week of SL-28 therapy. Complete responses, including the resolution of bone metastasis within 4 months of therapy, were confirmed by computed tomography and histology.Conclusion: SL-28 was efficient and safe approach in a patient with stage IV prostate cancer, supporting its potential in an allogeneic cell therapy for advanced malignancies.Keywords: prostate cancer, oncology, cell therapy, leucocyte-tells, SL-28, teazeled receptors, TezR, Universal receptive system